{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:38:49Z","timestamp":1790257129005,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1583,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1124\/jpet.119.264689","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T17:09:52Z","timestamp":1592932192000},"page":"489-498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["p38\u03b1 Regulates Expression of DUX4 in a Model of Facioscapulohumeral Muscular Dystrophy"],"prefix":"10.1016","volume":"374","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6445-1562","authenticated-orcid":false,"given":"L. Alejandro","family":"Rojas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Valentine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Accorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Maglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kazmirski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabi","family":"Tawil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cadavid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorin A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucienne","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron N.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Cacace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.264689_bib1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3390\/genes8030093","article-title":"Antisense oligonucleotides used to target the DUX4 mRNA as therapeutic approaches in FaciosScapuloHumeral muscular dystrophy (FSHD)","volume":"8","author":"Ansseau","year":"2017","journal-title":"Genes (Basel)"},{"key":"10.1124\/jpet.119.264689_bib2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/bcp.12063","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers","volume":"76","author":"Barbour","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.119.264689_bib3","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1093\/hmg\/ddt314","article-title":"Wnt\/\u03b2-catenin signaling suppresses DUX4 expression and prevents apoptosis of FSHD muscle cells","volume":"22","author":"Block","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.119.264689_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2044-5040-4-4","article-title":"High-throughput screening identifies inhibitors of DUX4-induced myoblast toxicity","volume":"4","author":"Bosnakovski","year":"2014","journal-title":"Skelet Muscle"},{"key":"10.1124\/jpet.119.264689_bib5","doi-asserted-by":"crossref","first-page":"eaaw7781","DOI":"10.1126\/sciadv.aaw7781","article-title":"A novel P300 inhibitor reverses DUX4-mediated global histone H3 hyperacetylation, target gene expression, and cell death","volume":"5","author":"Bosnakovski","year":"2019","journal-title":"Sci Adv"},{"key":"10.1124\/jpet.119.264689_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jneumeth.2008.01.009","article-title":"NbActiv4 medium improvement to Neurobasal\/B27 increases neuron synapse densities and network spike rates on multielectrode arrays","volume":"170","author":"Brewer","year":"2008","journal-title":"J Neurosci Methods"},{"key":"10.1124\/jpet.119.264689_bib7","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cell.2012.03.035","article-title":"A long ncRNA links copy number variation to a polycomb\/trithorax epigenetic switch in FSHD muscular dystrophy","volume":"149","author":"Cabianca","year":"2012","journal-title":"Cell"},{"key":"10.1124\/jpet.119.264689_bib8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/jmedgenet-2015-103436","article-title":"Allele-specific DNA hypomethylation characterises FSHD1 and FSHD2","volume":"53","author":"Calandra","year":"2016","journal-title":"J Med Genet"},{"key":"10.1124\/jpet.119.264689_bib9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13395-017-0134-x","article-title":"BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells","volume":"7","author":"Campbell","year":"2017","journal-title":"Skelet Muscle"},{"key":"10.1124\/jpet.119.264689_bib10","doi-asserted-by":"crossref","first-page":"e31023","DOI":"10.7554\/eLife.31023","article-title":"NuRD and CAF-1-mediated silencing of the D4Z4 array is modulated by DUX4-induced MBD3L proteins","volume":"7","author":"Campbell","year":"2018","journal-title":"eLife"},{"key":"10.1124\/jpet.119.264689_bib11","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1158\/1535-7163.MCT-13-0513","article-title":"Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity","volume":"13","author":"Campbell","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.119.264689_bib12","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/mt.2016.111","article-title":"Morpholino-mediated knockdown of DUX4 toward facioscapulohumeral muscular dystrophy therapeutics","volume":"24","author":"Chen","year":"2016","journal-title":"Mol Ther"},{"key":"10.1124\/jpet.119.264689_bib13","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1042\/BCJ20160189","article-title":"The epigenetic regulator Smchd1 contains a functional GHKL-type ATPase domain","volume":"473","author":"Chen","year":"2016","journal-title":"Biochem J"},{"key":"10.1124\/jpet.119.264689_bib14","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1093\/nar\/gkw141","article-title":"DUX4 recruits p300\/CBP through its C-terminus and induces global H3K27 acetylation changes","volume":"44","author":"Choi","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/jpet.119.264689_bib15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.molmed.2009.06.005","article-title":"p38(MAPK): stress responses from molecular mechanisms to therapeutics","volume":"15","author":"Coulthard","year":"2009","journal-title":"Trends Mol Med"},{"key":"10.1124\/jpet.119.264689_bib16","doi-asserted-by":"crossref","first-page":"11837","DOI":"10.1074\/jbc.RA118.002633","article-title":"Protein kinase A activation inhibits DUX4 gene expression in myotubes from patients with facioscapulohumeral muscular dystrophy","volume":"293","author":"Cruz","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.119.264689_bib17","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.bbamcr.2007.03.010","article-title":"p38 MAP-Kinases pathway regulation, function and role in human diseases","volume":"1773","author":"Cuenda","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.119.264689_bib18","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/art.24485","article-title":"Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies","volume":"60","author":"Damjanov","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.119.264689_bib19","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1212\/WNL.0000000000000797","article-title":"Population-based incidence and prevalence of facioscapulohumeral dystrophy","volume":"83","author":"Deenen","year":"2014","journal-title":"Neurology"},{"key":"10.1124\/jpet.119.264689_bib20","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/humu.21091","article-title":"Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD","volume":"30","author":"de Greef","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1124\/jpet.119.264689_bib21","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1093\/nar\/gkz005","article-title":"SMCHD1 is involved in de novo methylation of the DUX4-encoding D4Z4 macrosatellite","volume":"47","author":"Dion","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/jpet.119.264689_bib22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cell.2008.06.038","article-title":"Global mapping of the topography and magnitude of proteolytic events in apoptosis","volume":"134","author":"Dix","year":"2008","journal-title":"Cell"},{"key":"10.1124\/jpet.119.264689_bib23","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1159\/000430188","article-title":"Impact of p38 MAP kinase inhibitors on LPS-induced release of TNF-\u03b1 in whole blood and primary cells from different species","volume":"36","author":"Fehr","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"10.1124\/jpet.119.264689_bib24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1042\/BJ20041142","article-title":"The protein structures that shape caspase activity, specificity, activation and inhibition","volume":"384","author":"Fuentes-Prior","year":"2004","journal-title":"Biochem J"},{"key":"10.1124\/jpet.119.264689_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.devcel.2011.11.013","article-title":"DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy","volume":"22","author":"Geng","year":"2012","journal-title":"Dev Cell"},{"issue":"Suppl 1","key":"10.1124\/jpet.119.264689_bib26","doi-asserted-by":"crossref","first-page":"i77","DOI":"10.1136\/ard.2009.119479","article-title":"\u201cGo upstream, young man\u201d: lessons learned from the p38 saga","volume":"69","author":"Hammaker","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/jpet.119.264689_bib27","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1124\/jpet.108.139006","article-title":"Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity","volume":"327","author":"Hill","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264689_bib28","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1128\/MCB.00149-14","article-title":"Myogenic enhancers regulate expression of the facioscapulohumeral muscular dystrophy-associated DUX4 gene","volume":"34","author":"Himeda","year":"2014","journal-title":"Mol Cell Biol"},{"key":"10.1124\/jpet.119.264689_bib29","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1089\/ars.2014.6090","article-title":"Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease","volume":"22","author":"Himeda","year":"2015","journal-title":"Antioxid Redox Signal"},{"key":"10.1124\/jpet.119.264689_bib30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/acn3.158","article-title":"Expression of FSHD-related DUX4-FL alters proteostasis and induces TDP-43 aggregation","volume":"2","author":"Homma","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1124\/jpet.119.264689_bib31","first-page":"4419","article-title":"Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells","volume":"25","author":"Jagannathan","year":"2016","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.119.264689_bib32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.tig.2017.01.007","article-title":"The epigenetic regulator SMCHD1 in development and disease","volume":"33","author":"Jansz","year":"2017","journal-title":"Trends Genet"},{"key":"10.1124\/jpet.119.264689_bib33","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1093\/hmg\/dds284","article-title":"Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis","volume":"21","author":"Jones","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.119.264689_bib34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13148-015-0072-6","article-title":"Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy","volume":"7","author":"Jones","year":"2015","journal-title":"Clin Epigenetics"},{"key":"10.1124\/jpet.119.264689_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1868-7083-6-23","article-title":"Identifying diagnostic DNA methylation profiles for facioscapulohumeral muscular dystrophy in blood and saliva using bisulfite sequencing","volume":"6","author":"Jones","year":"2014","journal-title":"Clin Epigenetics"},{"key":"10.1124\/jpet.119.264689_bib36","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.mce.2006.03.017","article-title":"The p38 MAPK signaling pathway: a major regulator of skeletal muscle development","volume":"252","author":"Keren","year":"2006","journal-title":"Mol Cell Endocrinol"},{"key":"10.1124\/jpet.119.264689_bib37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2044-5040-2-5","article-title":"A novel whole-cell lysate kinase assay identifies substrates of the p38 MAPK in differentiating myoblasts","volume":"2","author":"Knight","year":"2012","journal-title":"Skelet Muscle"},{"key":"10.1124\/jpet.119.264689_bib38","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1128\/MCB.00688-13","article-title":"The emerging role of p38 mitogen-activated protein kinase in multiple sclerosis and its models","volume":"33","author":"Krementsov","year":"2013","journal-title":"Mol Cell Biol"},{"key":"10.1124\/jpet.119.264689_bib39","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ajpath.2012.07.007","article-title":"Generation of isogenic D4Z4 contracted and noncontracted immortal muscle cell clones from a mosaic patient: a cellular model for FSHD","volume":"181","author":"Krom","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1124\/jpet.119.264689_bib40","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1152\/physrev.2001.81.2.807","article-title":"Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation","volume":"81","author":"Kyriakis","year":"2001","journal-title":"Physiol Rev"},{"key":"10.1124\/jpet.119.264689_bib41","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1189044","article-title":"A unifying genetic model for facioscapulohumeral muscular dystrophy","volume":"329","author":"Lemmers","year":"2010","journal-title":"Science"},{"key":"10.1124\/jpet.119.264689_bib42","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ng.2454","article-title":"Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2","volume":"44","author":"Lemmers","year":"2012","journal-title":"Nat Genet"},{"key":"10.1124\/jpet.119.264689_bib43","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1136\/thoraxjnl-2012-202744","article-title":"Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial","volume":"68","author":"MacNee","year":"2013","journal-title":"Thorax"},{"key":"10.1124\/jpet.119.264689_bib44","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1111\/bph.12901","article-title":"p38 MAPK in cardioprotection - are we there yet?","volume":"172","author":"Martin","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.119.264689_bib45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1517\/13543784.2015.1006358","article-title":"Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease","volume":"24","author":"Norman","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.119.264689_bib46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.119.259663","article-title":"Clinically advanced p38 inhibitors suppress DUX4 expression in cellular and animal models of facioscapulohumeral muscular dystrophy","volume":"370","author":"Oliva","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264689_bib47","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1158\/1078-0432.CCR-15-1718","article-title":"A first-in-human phase I study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 dimesylate), in patients with advanced cancer","volume":"22","author":"Patnaik","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.119.264689_bib48","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/sj.emboj.7601587","article-title":"Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38\u03b1 in abrogating myoblast proliferation","volume":"26","author":"Perdiguero","year":"2007","journal-title":"EMBO J"},{"key":"10.1124\/jpet.119.264689_bib49","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1093\/hmg\/ddv315","article-title":"Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways","volume":"24","author":"Rickard","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.119.264689_bib50","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/jnen\/60.3.302","article-title":"Caspase 3 expression correlates with skeletal muscle apoptosis in Duchenne and facioscapulo human muscular dystrophy. A potential target for pharmacological treatment?","volume":"60","author":"Sandri","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1124\/jpet.119.264689_bib51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13395-016-0074-x","article-title":"Chromatin-wide and transcriptome profiling integration uncovers p38\u03b1 MAPK as a global regulator of skeletal muscle differentiation","volume":"6","author":"Segal\u00e9s","year":"2016","journal-title":"Skelet Muscle"},{"key":"10.1124\/jpet.119.264689_bib52","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fcell.2016.00091","article-title":"Regulation of muscle stem cell functions: a focus on the p38 MAPK signaling pathway","volume":"4","author":"Segal\u00e9s","year":"2016","journal-title":"Front Cell Dev Biol"},{"key":"10.1124\/jpet.119.264689_bib53","doi-asserted-by":"crossref","first-page":"e1006658","DOI":"10.1371\/journal.pgen.1006658","article-title":"DUX4-induced dsRNA and MYC mRNA stabilization activate apoptotic pathways in human cell models of facioscapulohumeral dystrophy","volume":"13","author":"Shadle","year":"2017","journal-title":"PLoS Genet"},{"key":"10.1124\/jpet.119.264689_bib54","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/ng1378","article-title":"p38 pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific loci","volume":"36","author":"Simone","year":"2004","journal-title":"Nat Genet"},{"key":"10.1124\/jpet.119.264689_bib55","doi-asserted-by":"crossref","first-page":"e1001181","DOI":"10.1371\/journal.pgen.1001181","article-title":"Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene","volume":"6","author":"Snider","year":"2010","journal-title":"PLoS Genet"},{"key":"10.1124\/jpet.119.264689_bib56","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3233\/JND-150077","article-title":"Immunohistochemical characterization of facioscapulohumeral muscular dystrophy muscle biopsies","volume":"2","author":"Statland","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"10.1124\/jpet.119.264689_bib57","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/mus.23949","article-title":"Risk of functional impairment in Facioscapulohumeral muscular dystrophy","volume":"49","author":"Statland","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1124\/jpet.119.264689_bib58","doi-asserted-by":"crossref","first-page":"e38779","DOI":"10.1371\/journal.pone.0038779","article-title":"Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles","volume":"7","author":"Tasca","year":"2012","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.264689_bib59","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1212\/WNL.0000000000001783","volume":"85","author":"Tawil","year":"2015","journal-title":"Neurology"},{"key":"10.1124\/jpet.119.264689_bib60","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2044-5040-4-12","article-title":"Facioscapulohumeral dystrophy: the path to consensus on pathophysiology","volume":"4","author":"Tawil","year":"2014","journal-title":"Skelet Muscle"},{"key":"10.1124\/jpet.119.264689_bib61","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13395-016-0115-5","article-title":"Skeletal muscle characteristics are preserved in hTERT\/cdk4 human myogenic cell lines","volume":"6","author":"Thorley","year":"2016","journal-title":"Skelet Muscle"},{"key":"10.1124\/jpet.119.264689_bib62","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0022-3565(24)39230-4","article-title":"SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence","volume":"293","author":"Underwood","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264689_bib63","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/ejhg.2015.55","article-title":"Double SMCHD1 variants in FSHD2: the synergistic effect of two SMCHD1 variants on D4Z4 hypomethylation and disease penetrance in FSHD2","volume":"24","author":"van den Boogaard","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"10.1124\/jpet.119.264689_bib64","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ajhg.2016.03.013","article-title":"Mutations in DNMT3B modify epigenetic repression of the D4Z4 repeat and the penetrance of facioscapulohumeral dystrophy","volume":"98","author":"van den Boogaard","year":"2016","journal-title":"Am J Hum Genet"},{"key":"10.1124\/jpet.119.264689_bib65","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/hmg\/ddy400","article-title":"Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development","volume":"28","author":"van den Heuvel","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.119.264689_bib66","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/ng1262","article-title":"Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy","volume":"35","author":"van Overveld","year":"2003","journal-title":"Nat Genet"},{"key":"10.1124\/jpet.119.264689_bib67","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.omtm.2017.12.005","article-title":"Pre-clinical safety and off-target studies to support translation of AAV-mediated RNAi therapy for FSHD","volume":"8","author":"Wallace","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1124\/jpet.119.264689_bib68","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/hmg\/ddy364","article-title":"MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD","volume":"28","author":"Wang","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.119.264689_bib69","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/ng.3846","article-title":"Conservation and innovation in the DUX4-family gene network","volume":"49","author":"Whiddon","year":"2017","journal-title":"Nat Genet"},{"key":"10.1124\/jpet.119.264689_bib70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1741-7007-8-47","article-title":"A central role for p38 MAPK in the early transcriptional response to stress","volume":"8","author":"Whitmarsh","year":"2010","journal-title":"BMC Biol"},{"key":"10.1124\/jpet.119.264689_bib71","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1093\/hmg\/ddu270","article-title":"P38\u03b1 MAPK underlies muscular dystrophy and myofiber death through a Bax-dependent mechanism","volume":"23","author":"Wissing","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.119.264689_bib72","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1093\/hmg\/ddu251","article-title":"DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle","volume":"23","author":"Yao","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.119.264689_bib73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.cr.7290257","article-title":"Activation and signaling of the p38 MAP kinase pathway","volume":"15","author":"Zarubin","year":"2005","journal-title":"Cell Res"},{"key":"10.1124\/jpet.119.264689_bib74","doi-asserted-by":"crossref","first-page":"e1000559","DOI":"10.1371\/journal.pgen.1000559","article-title":"Specific loss of histone H3 lysine 9 trimethylation and HP1\u03b3\/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD)","volume":"5","author":"Zeng","year":"2009","journal-title":"PLoS Genet"},{"key":"10.1124\/jpet.119.264689_bib75","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1074\/jbc.274.8.5193","article-title":"p38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation. Participation of the Mef2c transcription factor","volume":"274","author":"Zetser","year":"1999","journal-title":"J Biol Chem"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524258328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524258328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.264689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T06:12:05Z","timestamp":1739945525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524258328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0022356524258328"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.264689","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/700195","asserted-by":"object"}]},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"p38\u03b1 Regulates Expression of DUX4 in a Model of Facioscapulohumeral Muscular Dystrophy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.264689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s)","name":"copyright","label":"Copyright"}]}}